10x Genomics filed suit against Element Biosciences, alleging the Aviti24 multiomic platform infringes multiple spatial technology patents licensed from Harvard University. The complaint, filed in U.S. District Court for the District of Delaware, targets specific patent numbers tied to analyte detection and amplicon sequencing methods, seeking damages, attorneys’ fees, and a permanent injunction. Element disputed the allegations, saying it believes the claims lack merit and that the lawsuit reflects a broader pattern of leveraging the same patent portfolio to limit competition in spatial biology. Element said it plans to roll out in-tissue spatial sequencing products later this year on the Aviti24 platform for both fresh-frozen and FFPE tissues. The dispute centers on technologies that bundle RNA, protein, morphology, and spatial context in single workflows, and it raises stakes for labs evaluating which platforms can scale at clinical and research pace without IP friction.